AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listing of claims in the application. No new matter is added.

Listing of Claims:

1-14. (CANCELED)

- 15. (PREVIOUSLY PRESENTED) The method of claim 27, wherein a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof is administered simultaneously with the other antitumor agent.
- 16. (PREVIOUSLY PRESENTED) The method of claim 27, wherein a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof is administered in combination with the other antitumor agent sequentially.

17-26. (CANCELED)

27. (CURRENTLY AMENDED) A method for treating a patient suffering from at least one malignant tumor selected from the group consisting of blood cancer, leukemia, human colon adenocarcinoma, gastrointestinal cancer, lung cancer, breast cancer, and prostate cancer, the method comprising administering a therapeutically effective amount of at least one compound selected from the group consisting of (E)-4-[2-[2-[N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[N-acetyl-N-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[(p-methoxyphenyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[(p-methoxyphenyl]amino]phenyl]ethenyl]

methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, (E)-4-[2-[2-[N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-(2-hydroxyethyl)-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, and (E)-4-[2-[2-[N-(2-hydroxyethyl)-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine or a pharmaceutically acceptable salt thereof in combination with at least one other antitumor agent to the patient in need thereof, wherein the other antitumor agent is selected from the group consisting of cisplatin and carboplatin, and the therapeutically effective amount of the at least one compound in combination with the at least one antitumor agent gives a synergistic inhibitory effect.